M.D. - Pomeranian Medical University, Szczecin, Poland
Ph.D. - Pomeranian Medical University, Szczecin, Poland
Residency in Anatomic Pathology - Pomeranian Medical University, Szczecin, Poland
Postdoctoral training – Fox Chase Cancer Center, Philadelphia, PA
Instructor, Pomeranian Medical University, Szczecin, Poland (1993-2000)
Resident pathologist, Regional Cancer Center, Szczecin, Poland (2000)
Postdoctoral Associate, Fox Chase Cancer Center, Philadelphia (2001-2010)
Dr. Magdalena Karbowniczek received her M.D. in 1993 and Ph.D. in tumor pathology in 1998 from Pomeranian Medical University in Poland. She is also board certified in Anatomic Pathology and served as a histopathology consultant for several years prior to coming to the USA. She received her postdoctoral training in Dr. Elizabeth Henske’s laboratory at the Fox Chase Cancer Center, Philadelphia.
Tuberous sclerosis complex, Notch signaling, cell fate decision, origin of cancer, developmental biology, tumor suppressor genes, cancer therapy. One of key questions in cancer research is how cancer starts. However, despite years of studies, the hunt for cancer’s roots has been failing to deliver this answer. Research in my laboratory is design to find the origin of cells that start a rare form of human malignancy called Tuberous Sclerosis Complex. However, the results of these studies are relevant for very common human cancers, as we discovered that the cells that give rise to tumors in Tuberous Sclerosis Complex could be the same for melanoma, brain tumors and some types of lung cancer. In our laboratory, we are trying to understand how cell proteins and genes interact with each other during the embryonic development and later in life, to change a normal cell into the very first cancer cell. We use recently developed technologies to manipulate these genes and proteins in a mouse to mimic the development of human cancer. Understanding of these early stages in cancer development will ultimately lead to therapies that my even prevent some cancers from development. Our work is also focused on understanding how dysfunction of tumor suppressor genes leads to cancer development. The importance of these studies are underscored by the number of mutations within tumor suppressor genes and their association with increased risk of cancer. To achieve these objectives we apply to our research syngeneic and genetically modified mouse (GEM) models of cancer, drugs targeting downstream effectors of malfunctioning genes and the state-of-art experimental approaches such as fluorescent-activating cell sorting, digital pathology and several biochemical and molecular biology assays. We will accept graduate students for laboratory rotations who are strongly motivated and interested in contributing to cutting-edge research in the area of tumor cell biology, cancer progression and initiation. The acceptance of a student will be decided on case to case basis depending on the availability of funds to support his/her research and an enter interview with a principle investigator.